| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hematologic Neoplasms | 35 | 2023 | 321 | 11.290 |
Why?
|
| Germ-Line Mutation | 31 | 2023 | 317 | 9.140 |
Why?
|
| Genetic Predisposition to Disease | 42 | 2022 | 2214 | 6.710 |
Why?
|
| Leukemia, Myeloid, Acute | 40 | 2023 | 736 | 6.630 |
Why?
|
| DNA Methylation | 42 | 2023 | 601 | 5.790 |
Why?
|
| Myelodysplastic Syndromes | 30 | 2023 | 338 | 5.520 |
Why?
|
| Proto-Oncogene Proteins | 25 | 2022 | 650 | 3.630 |
Why?
|
| Cytosine | 18 | 2020 | 125 | 3.610 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferases | 17 | 2022 | 54 | 3.290 |
Why?
|
| Myeloproliferative Disorders | 10 | 2023 | 113 | 3.140 |
Why?
|
| Hematopoiesis | 20 | 2023 | 164 | 3.000 |
Why?
|
| 5-Methylcytosine | 19 | 2022 | 106 | 2.990 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 11 | 2022 | 50 | 2.840 |
Why?
|
| Leukemia | 12 | 2022 | 316 | 2.540 |
Why?
|
| Epigenesis, Genetic | 22 | 2020 | 447 | 2.330 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 23 | 2023 | 863 | 2.320 |
Why?
|
| Leukemia, Myeloid | 11 | 2023 | 250 | 2.290 |
Why?
|
| Neuroblastoma | 9 | 2022 | 365 | 2.130 |
Why?
|
| Humans | 185 | 2023 | 83576 | 1.890 |
Why?
|
| DNA-Binding Proteins | 20 | 2020 | 1190 | 1.840 |
Why?
|
| Gene Expression Regulation, Neoplastic | 21 | 2022 | 1181 | 1.830 |
Why?
|
| Genetic Testing | 11 | 2022 | 513 | 1.720 |
Why?
|
| Hematopoietic Stem Cells | 12 | 2023 | 292 | 1.660 |
Why?
|
| Dioxygenases | 16 | 2020 | 75 | 1.640 |
Why?
|
| Blood Donors | 3 | 2016 | 26 | 1.620 |
Why?
|
| Mixed Function Oxygenases | 4 | 2022 | 68 | 1.600 |
Why?
|
| Thrombocytopenia | 6 | 2021 | 176 | 1.580 |
Why?
|
| Mutation | 35 | 2023 | 3882 | 1.570 |
Why?
|
| High-Throughput Nucleotide Sequencing | 6 | 2020 | 428 | 1.500 |
Why?
|
| CpG Islands | 11 | 2020 | 146 | 1.490 |
Why?
|
| DNA Copy Number Variations | 2 | 2020 | 171 | 1.470 |
Why?
|
| Neoplasms | 14 | 2022 | 2789 | 1.430 |
Why?
|
| Germ Cells | 14 | 2023 | 110 | 1.420 |
Why?
|
| DEAD-box RNA Helicases | 4 | 2023 | 59 | 1.410 |
Why?
|
| Transplantation Conditioning | 20 | 2018 | 372 | 1.260 |
Why?
|
| Histones | 10 | 2023 | 296 | 1.250 |
Why?
|
| Azacitidine | 11 | 2020 | 134 | 1.230 |
Why?
|
| Proto-Oncogene Proteins c-ets | 4 | 2022 | 25 | 1.200 |
Why?
|
| DNA Mutational Analysis | 9 | 2016 | 524 | 1.200 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 5 | 2010 | 171 | 1.140 |
Why?
|
| Graft vs Host Disease | 9 | 2023 | 359 | 1.040 |
Why?
|
| Lymphoma | 6 | 2016 | 259 | 1.030 |
Why?
|
| Cell Transformation, Neoplastic | 7 | 2023 | 412 | 1.000 |
Why?
|
| Alleles | 5 | 2021 | 1108 | 0.990 |
Why?
|
| Proto-Oncogene Proteins c-myc | 3 | 2020 | 115 | 0.990 |
Why?
|
| Nuclear Proteins | 8 | 2015 | 692 | 0.950 |
Why?
|
| Neoplasms, Second Primary | 5 | 2021 | 249 | 0.930 |
Why?
|
| N-Myc Proto-Oncogene Protein | 2 | 2022 | 36 | 0.930 |
Why?
|
| Bone Marrow | 4 | 2023 | 429 | 0.910 |
Why?
|
| Hypoxia-Inducible Factor 1 | 1 | 2022 | 42 | 0.880 |
Why?
|
| Repressor Proteins | 5 | 2021 | 398 | 0.880 |
Why?
|
| Leukemia, Erythroblastic, Acute | 2 | 2021 | 29 | 0.880 |
Why?
|
| Globins | 1 | 2021 | 31 | 0.870 |
Why?
|
| Neoplastic Stem Cells | 3 | 2016 | 142 | 0.840 |
Why?
|
| Female | 75 | 2023 | 43618 | 0.830 |
Why?
|
| Genome, Human | 6 | 2022 | 742 | 0.830 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2022 | 135 | 0.830 |
Why?
|
| Genetic Association Studies | 4 | 2021 | 290 | 0.810 |
Why?
|
| Transcription Factors | 10 | 2020 | 1492 | 0.810 |
Why?
|
| Receptors, Colony-Stimulating Factor | 1 | 2020 | 5 | 0.810 |
Why?
|
| Cell Line, Tumor | 20 | 2022 | 2378 | 0.790 |
Why?
|
| Cell Differentiation | 10 | 2017 | 1394 | 0.760 |
Why?
|
| Myeloid Cells | 5 | 2017 | 96 | 0.750 |
Why?
|
| Xeroderma Pigmentosum | 1 | 2019 | 9 | 0.740 |
Why?
|
| Animals | 47 | 2023 | 25939 | 0.730 |
Why?
|
| Erythropoiesis | 3 | 2013 | 52 | 0.710 |
Why?
|
| Male | 66 | 2023 | 40132 | 0.710 |
Why?
|
| DNA Modification Methylases | 4 | 2022 | 24 | 0.710 |
Why?
|
| Precision Medicine | 2 | 2021 | 373 | 0.710 |
Why?
|
| Antineoplastic Agents | 11 | 2022 | 2323 | 0.700 |
Why?
|
| Promoter Regions, Genetic | 13 | 2020 | 920 | 0.690 |
Why?
|
| Aged | 50 | 2021 | 18018 | 0.680 |
Why?
|
| Antimetabolites, Antineoplastic | 6 | 2017 | 236 | 0.660 |
Why?
|
| Adult | 48 | 2023 | 25182 | 0.660 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 3 | 2016 | 50 | 0.640 |
Why?
|
| Genes, Tumor Suppressor | 6 | 2018 | 157 | 0.630 |
Why?
|
| Blood Platelet Disorders | 2 | 2021 | 8 | 0.620 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 2 | 2017 | 144 | 0.620 |
Why?
|
| Lymphoma, B-Cell | 2 | 2020 | 102 | 0.610 |
Why?
|
| Drug Resistance, Neoplasm | 5 | 2017 | 580 | 0.600 |
Why?
|
| X Chromosome Inactivation | 2 | 2015 | 28 | 0.580 |
Why?
|
| Mice | 33 | 2021 | 10897 | 0.560 |
Why?
|
| Cord Blood Stem Cell Transplantation | 5 | 2016 | 93 | 0.560 |
Why?
|
| Prognosis | 21 | 2022 | 3616 | 0.550 |
Why?
|
| Consensus | 2 | 2022 | 308 | 0.550 |
Why?
|
| Transplantation, Homologous | 21 | 2018 | 984 | 0.550 |
Why?
|
| Chromosomes, Human, X | 1 | 2015 | 54 | 0.540 |
Why?
|
| Models, Biological | 5 | 2021 | 1747 | 0.540 |
Why?
|
| Donor Selection | 1 | 2015 | 67 | 0.540 |
Why?
|
| Apolipoproteins E | 1 | 2015 | 118 | 0.530 |
Why?
|
| RNA, Messenger | 9 | 2023 | 1940 | 0.530 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2014 | 276 | 0.530 |
Why?
|
| Cell Proliferation | 8 | 2018 | 1558 | 0.520 |
Why?
|
| Preleukemia | 1 | 2014 | 10 | 0.520 |
Why?
|
| Antineoplastic Agents, Alkylating | 2 | 2017 | 137 | 0.510 |
Why?
|
| Clonal Evolution | 1 | 2014 | 15 | 0.510 |
Why?
|
| Isocitrate Dehydrogenase | 5 | 2023 | 52 | 0.510 |
Why?
|
| Tumor Suppressor Protein p53 | 5 | 2021 | 372 | 0.500 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 3 | 2022 | 177 | 0.500 |
Why?
|
| Erythroid Cells | 1 | 2013 | 14 | 0.500 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2012 | 448 | 0.500 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 5 | 2023 | 120 | 0.500 |
Why?
|
| Epigenomics | 5 | 2019 | 88 | 0.500 |
Why?
|
| DNA Repair Enzymes | 1 | 2014 | 52 | 0.490 |
Why?
|
| Stem Cell Transplantation | 4 | 2012 | 181 | 0.490 |
Why?
|
| Genetic Variation | 5 | 2022 | 1351 | 0.480 |
Why?
|
| Dacarbazine | 1 | 2014 | 102 | 0.480 |
Why?
|
| Pedigree | 8 | 2020 | 965 | 0.480 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2017 | 348 | 0.480 |
Why?
|
| Sex Characteristics | 1 | 2015 | 305 | 0.480 |
Why?
|
| Leukemia, Myelomonocytic, Chronic | 4 | 2021 | 20 | 0.480 |
Why?
|
| Antigens, CD34 | 10 | 2017 | 156 | 0.480 |
Why?
|
| Middle Aged | 49 | 2021 | 24598 | 0.480 |
Why?
|
| Haploinsufficiency | 2 | 2013 | 60 | 0.480 |
Why?
|
| Mitoxantrone | 4 | 2020 | 68 | 0.470 |
Why?
|
| Bone Marrow Cells | 3 | 2017 | 247 | 0.470 |
Why?
|
| Hypoxia | 4 | 2022 | 619 | 0.470 |
Why?
|
| Karyopherins | 1 | 2012 | 13 | 0.460 |
Why?
|
| Chromosome Deletion | 4 | 2011 | 228 | 0.460 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 8 | 2018 | 2390 | 0.450 |
Why?
|
| Induction Chemotherapy | 2 | 2018 | 147 | 0.450 |
Why?
|
| Colon | 1 | 2015 | 500 | 0.440 |
Why?
|
| Histone Code | 1 | 2012 | 18 | 0.440 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2012 | 121 | 0.430 |
Why?
|
| Tissue Donors | 3 | 2012 | 437 | 0.420 |
Why?
|
| Colonic Neoplasms | 1 | 2015 | 550 | 0.420 |
Why?
|
| Breast Neoplasms | 4 | 2022 | 2830 | 0.410 |
Why?
|
| Young Adult | 21 | 2021 | 5835 | 0.400 |
Why?
|
| Burkitt Lymphoma | 1 | 2010 | 31 | 0.400 |
Why?
|
| GATA2 Transcription Factor | 3 | 2023 | 11 | 0.390 |
Why?
|
| Histone Deacetylase Inhibitors | 4 | 2017 | 82 | 0.390 |
Why?
|
| Hematology | 2 | 2020 | 29 | 0.390 |
Why?
|
| Mediastinal Neoplasms | 1 | 2010 | 45 | 0.380 |
Why?
|
| Antibodies, Neoplasm | 6 | 2010 | 84 | 0.380 |
Why?
|
| Acute Disease | 11 | 2022 | 809 | 0.380 |
Why?
|
| Cell-Free Nucleic Acids | 2 | 2021 | 60 | 0.370 |
Why?
|
| Biomarkers | 4 | 2021 | 1647 | 0.370 |
Why?
|
| Chromosomes, Human, Pair 5 | 5 | 2021 | 108 | 0.370 |
Why?
|
| Cell Hypoxia | 3 | 2022 | 166 | 0.370 |
Why?
|
| Proto-Oncogene Proteins c-kit | 2 | 2011 | 79 | 0.360 |
Why?
|
| Adenocarcinoma | 2 | 2015 | 1155 | 0.360 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 2009 | 86 | 0.360 |
Why?
|
| Base Sequence | 10 | 2019 | 2312 | 0.350 |
Why?
|
| Family | 4 | 2016 | 308 | 0.350 |
Why?
|
| Genetic Counseling | 3 | 2021 | 96 | 0.350 |
Why?
|
| Mastocytosis | 1 | 2008 | 13 | 0.350 |
Why?
|
| Abnormalities, Multiple | 1 | 2010 | 232 | 0.350 |
Why?
|
| Telomerase | 3 | 2020 | 53 | 0.340 |
Why?
|
| RNA Splicing | 2 | 2015 | 135 | 0.340 |
Why?
|
| Gene Expression Profiling | 9 | 2017 | 1351 | 0.340 |
Why?
|
| Transcriptional Activation | 2 | 2020 | 276 | 0.340 |
Why?
|
| DNA | 2 | 2011 | 1270 | 0.340 |
Why?
|
| Disease Susceptibility | 2 | 2023 | 185 | 0.330 |
Why?
|
| Aging | 3 | 2023 | 659 | 0.330 |
Why?
|
| Aged, 80 and over | 19 | 2023 | 6419 | 0.330 |
Why?
|
| HMGA2 Protein | 1 | 2007 | 14 | 0.330 |
Why?
|
| Genomics | 8 | 2022 | 664 | 0.320 |
Why?
|
| Cytarabine | 4 | 2020 | 216 | 0.320 |
Why?
|
| MicroRNAs | 2 | 2015 | 523 | 0.320 |
Why?
|
| Cell Line | 5 | 2021 | 2429 | 0.320 |
Why?
|
| BRCA1 Protein | 2 | 2021 | 189 | 0.310 |
Why?
|
| Treatment Outcome | 18 | 2018 | 7773 | 0.310 |
Why?
|
| Translocation, Genetic | 4 | 2021 | 265 | 0.300 |
Why?
|
| Leukemia, Promyelocytic, Acute | 2 | 2018 | 49 | 0.300 |
Why?
|
| Adolescent | 17 | 2021 | 8803 | 0.300 |
Why?
|
| Sulfonamides | 2 | 2021 | 297 | 0.300 |
Why?
|
| Risk Assessment | 3 | 2015 | 2220 | 0.290 |
Why?
|
| Enzyme Inhibitors | 3 | 2013 | 632 | 0.290 |
Why?
|
| Chromosome Aberrations | 4 | 2021 | 384 | 0.290 |
Why?
|
| Biomarkers, Tumor | 4 | 2021 | 1439 | 0.290 |
Why?
|
| Telomere | 3 | 2021 | 104 | 0.280 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferase 1 | 4 | 2014 | 18 | 0.280 |
Why?
|
| Gene Expression Regulation | 5 | 2021 | 1889 | 0.280 |
Why?
|
| Clone Cells | 2 | 2023 | 211 | 0.270 |
Why?
|
| Survival Analysis | 9 | 2021 | 1530 | 0.270 |
Why?
|
| Risk | 4 | 2021 | 671 | 0.270 |
Why?
|
| Pancytopenia | 2 | 2022 | 23 | 0.270 |
Why?
|
| Pyrimidines | 3 | 2021 | 366 | 0.260 |
Why?
|
| Fusion Proteins, bcr-abl | 3 | 2010 | 108 | 0.260 |
Why?
|
| Gene Expression | 5 | 2023 | 1276 | 0.260 |
Why?
|
| Risk Factors | 9 | 2021 | 5296 | 0.260 |
Why?
|
| RNA Interference | 4 | 2018 | 361 | 0.260 |
Why?
|
| Phenotype | 10 | 2022 | 2314 | 0.260 |
Why?
|
| Clinical Decision-Making | 3 | 2022 | 252 | 0.260 |
Why?
|
| Mice, Transgenic | 9 | 2013 | 1503 | 0.260 |
Why?
|
| Biology | 2 | 2021 | 45 | 0.260 |
Why?
|
| Zinc Fingers | 2 | 2023 | 56 | 0.250 |
Why?
|
| Remission Induction | 10 | 2020 | 709 | 0.250 |
Why?
|
| Mice, Inbred C57BL | 10 | 2020 | 3024 | 0.250 |
Why?
|
| Fibroblasts | 3 | 2022 | 699 | 0.250 |
Why?
|
| RNA, Small Interfering | 4 | 2018 | 540 | 0.250 |
Why?
|
| Antibodies, Monoclonal | 6 | 2010 | 1356 | 0.250 |
Why?
|
| Disease Management | 3 | 2021 | 322 | 0.250 |
Why?
|
| alpha Karyopherins | 1 | 2023 | 10 | 0.240 |
Why?
|
| Geriatric Assessment | 2 | 2015 | 161 | 0.240 |
Why?
|
| Hematologic Diseases | 2 | 2022 | 79 | 0.240 |
Why?
|
| Haplotypes | 3 | 2016 | 638 | 0.240 |
Why?
|
| Anemia, Aplastic | 2 | 2021 | 29 | 0.240 |
Why?
|
| Germinal Center | 2 | 2015 | 51 | 0.240 |
Why?
|
| Sequence Analysis, DNA | 5 | 2019 | 834 | 0.240 |
Why?
|
| Binding Sites | 4 | 2015 | 1081 | 0.240 |
Why?
|
| Cell Cycle Proteins | 4 | 2015 | 380 | 0.230 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2023 | 104 | 0.230 |
Why?
|
| Age of Onset | 2 | 2021 | 302 | 0.230 |
Why?
|
| Australia | 1 | 2023 | 96 | 0.230 |
Why?
|
| Tetrasomy | 1 | 2022 | 2 | 0.230 |
Why?
|
| Histone Demethylases | 2 | 2023 | 25 | 0.230 |
Why?
|
| Kaplan-Meier Estimate | 8 | 2018 | 854 | 0.230 |
Why?
|
| Checkpoint Kinase 2 | 1 | 2022 | 23 | 0.230 |
Why?
|
| Neoplasm Proteins | 3 | 2015 | 533 | 0.220 |
Why?
|
| Adenine Nucleotides | 2 | 2013 | 63 | 0.220 |
Why?
|
| Arabinonucleosides | 2 | 2013 | 39 | 0.220 |
Why?
|
| Cell Movement | 3 | 2022 | 737 | 0.220 |
Why?
|
| Genes, p53 | 4 | 1997 | 109 | 0.220 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 2 | 2014 | 135 | 0.220 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 2 | 2016 | 161 | 0.220 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2022 | 49 | 0.220 |
Why?
|
| Cyclophosphamide | 1 | 2023 | 295 | 0.220 |
Why?
|
| Mastocytosis, Systemic | 2 | 2014 | 11 | 0.220 |
Why?
|
| Genotype | 4 | 2021 | 1828 | 0.220 |
Why?
|
| DNA Topoisomerases, Type II | 1 | 2021 | 19 | 0.220 |
Why?
|
| HLA Antigens | 2 | 2016 | 231 | 0.210 |
Why?
|
| Quantitative Trait Loci | 3 | 2014 | 564 | 0.210 |
Why?
|
| Retinoblastoma-Like Protein p130 | 1 | 2021 | 7 | 0.210 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 2 | 2012 | 67 | 0.210 |
Why?
|
| Morpholines | 1 | 2021 | 64 | 0.210 |
Why?
|
| Megakaryocytes | 1 | 2021 | 37 | 0.210 |
Why?
|
| Telomere Shortening | 1 | 2021 | 23 | 0.210 |
Why?
|
| Fetal Blood | 3 | 2017 | 90 | 0.210 |
Why?
|
| Molecular Sequence Data | 12 | 2015 | 3024 | 0.200 |
Why?
|
| Glioma | 1 | 2023 | 276 | 0.200 |
Why?
|
| Bias | 1 | 2021 | 126 | 0.200 |
Why?
|
| Cysteine | 2 | 2011 | 131 | 0.200 |
Why?
|
| Janus Kinase 2 | 2 | 2019 | 61 | 0.200 |
Why?
|
| Mice, Knockout | 6 | 2015 | 1883 | 0.200 |
Why?
|
| Fetus | 1 | 2021 | 224 | 0.200 |
Why?
|
| Isoenzymes | 2 | 2012 | 269 | 0.200 |
Why?
|
| Multiple Myeloma | 2 | 2018 | 299 | 0.200 |
Why?
|
| Alcohol Oxidoreductases | 1 | 2020 | 17 | 0.190 |
Why?
|
| Minority Groups | 1 | 2021 | 127 | 0.190 |
Why?
|
| BRCA2 Protein | 1 | 2021 | 146 | 0.190 |
Why?
|
| Induced Pluripotent Stem Cells | 1 | 2021 | 91 | 0.190 |
Why?
|
| Dose-Response Relationship, Drug | 7 | 2014 | 1948 | 0.190 |
Why?
|
| Gene Frequency | 2 | 2019 | 669 | 0.190 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2020 | 62 | 0.190 |
Why?
|
| Mutation, Missense | 3 | 2018 | 273 | 0.190 |
Why?
|
| Face | 1 | 2020 | 120 | 0.190 |
Why?
|
| Alternative Splicing | 4 | 2015 | 198 | 0.190 |
Why?
|
| Chromosome Disorders | 1 | 2020 | 114 | 0.190 |
Why?
|
| Indoles | 1 | 2021 | 315 | 0.190 |
Why?
|
| Karyotype | 1 | 2019 | 32 | 0.180 |
Why?
|
| Molecular Sequence Annotation | 1 | 2019 | 66 | 0.180 |
Why?
|
| Proteins | 2 | 2008 | 758 | 0.180 |
Why?
|
| Unrelated Donors | 2 | 2017 | 49 | 0.180 |
Why?
|
| Cognitive Dysfunction | 1 | 2021 | 116 | 0.180 |
Why?
|
| Endodeoxyribonucleases | 1 | 2018 | 11 | 0.180 |
Why?
|
| Gene-Environment Interaction | 2 | 2017 | 97 | 0.180 |
Why?
|
| Superoxides | 1 | 2019 | 73 | 0.180 |
Why?
|
| Transcription, Genetic | 4 | 2020 | 1118 | 0.170 |
Why?
|
| Glutarates | 2 | 2023 | 7 | 0.170 |
Why?
|
| B-Lymphocytes | 2 | 2015 | 710 | 0.170 |
Why?
|
| Sequence Analysis, RNA | 2 | 2017 | 207 | 0.170 |
Why?
|
| Muscle Proteins | 1 | 1999 | 133 | 0.170 |
Why?
|
| Gene Expression Regulation, Leukemic | 2 | 2016 | 90 | 0.170 |
Why?
|
| Interleukin-6 | 3 | 2023 | 239 | 0.170 |
Why?
|
| Azepines | 2 | 2015 | 20 | 0.170 |
Why?
|
| Clinical Trials as Topic | 3 | 2018 | 1154 | 0.170 |
Why?
|
| Protein Kinases | 1 | 1999 | 203 | 0.170 |
Why?
|
| Histocompatibility Testing | 3 | 2017 | 154 | 0.170 |
Why?
|
| Cytokines | 2 | 2019 | 754 | 0.170 |
Why?
|
| Monoclonal Gammopathy of Undetermined Significance | 1 | 2018 | 8 | 0.170 |
Why?
|
| Bacterial Physiological Phenomena | 1 | 2018 | 40 | 0.170 |
Why?
|
| Asymptomatic Diseases | 1 | 2018 | 40 | 0.170 |
Why?
|
| Mammary Neoplasms, Experimental | 5 | 1997 | 126 | 0.160 |
Why?
|
| Exome | 2 | 2015 | 125 | 0.160 |
Why?
|
| Zebrafish Proteins | 5 | 1997 | 143 | 0.160 |
Why?
|
| Combined Modality Therapy | 5 | 2017 | 1644 | 0.160 |
Why?
|
| Up-Regulation | 3 | 2015 | 698 | 0.160 |
Why?
|
| CCAAT-Enhancer-Binding Proteins | 2 | 2014 | 33 | 0.160 |
Why?
|
| Genes, Dominant | 1 | 2017 | 116 | 0.160 |
Why?
|
| Exons | 3 | 2015 | 446 | 0.160 |
Why?
|
| Antibodies, Monoclonal, Humanized | 7 | 2011 | 918 | 0.150 |
Why?
|
| DNA Repair | 1 | 2019 | 351 | 0.150 |
Why?
|
| Alemtuzumab | 7 | 2011 | 83 | 0.150 |
Why?
|
| Health Planning Guidelines | 1 | 2016 | 24 | 0.150 |
Why?
|
| Gene Silencing | 3 | 2012 | 170 | 0.150 |
Why?
|
| Gene Expression Regulation, Developmental | 2 | 2011 | 610 | 0.150 |
Why?
|
| Tretinoin | 2 | 2018 | 125 | 0.150 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 2016 | 18 | 0.150 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2019 | 398 | 0.150 |
Why?
|
| Succinic Acid | 1 | 2015 | 6 | 0.150 |
Why?
|
| Sulfones | 1 | 2016 | 42 | 0.150 |
Why?
|
| Enhancer Elements, Genetic | 2 | 2015 | 259 | 0.150 |
Why?
|
| Paramyxoviridae | 1 | 2015 | 10 | 0.150 |
Why?
|
| Haploidy | 1 | 2016 | 30 | 0.150 |
Why?
|
| Hemoglobinuria, Paroxysmal | 1 | 2015 | 5 | 0.150 |
Why?
|
| Leukemia, Radiation-Induced | 1 | 2015 | 14 | 0.140 |
Why?
|
| Mice, Nude | 2 | 2021 | 762 | 0.140 |
Why?
|
| Fumarates | 1 | 2015 | 26 | 0.140 |
Why?
|
| Child | 7 | 2022 | 6697 | 0.140 |
Why?
|
| Glycine | 1 | 2016 | 90 | 0.140 |
Why?
|
| Melphalan | 3 | 2011 | 96 | 0.140 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2014 | 2317 | 0.140 |
Why?
|
| Cells, Cultured | 3 | 2021 | 2762 | 0.140 |
Why?
|
| Lymphocyte Depletion | 2 | 2017 | 97 | 0.140 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2019 | 520 | 0.140 |
Why?
|
| Cytidine Deaminase | 1 | 2015 | 43 | 0.140 |
Why?
|
| Community-Acquired Infections | 1 | 2015 | 61 | 0.140 |
Why?
|
| Protein Isoforms | 3 | 2013 | 262 | 0.140 |
Why?
|
| Patients | 1 | 2016 | 97 | 0.140 |
Why?
|
| Histone-Lysine N-Methyltransferase | 2 | 2013 | 147 | 0.140 |
Why?
|
| Mitochondria | 1 | 2019 | 528 | 0.140 |
Why?
|
| Survival Rate | 7 | 2014 | 1843 | 0.140 |
Why?
|
| Age Factors | 6 | 2018 | 1817 | 0.140 |
Why?
|
| Models, Molecular | 4 | 2015 | 1276 | 0.140 |
Why?
|
| Ureter | 1 | 1996 | 85 | 0.130 |
Why?
|
| WT1 Proteins | 1 | 2014 | 18 | 0.130 |
Why?
|
| Ascorbic Acid | 1 | 2015 | 38 | 0.130 |
Why?
|
| Genetic Diseases, Inborn | 1 | 2015 | 100 | 0.130 |
Why?
|
| Respiratory Tract Infections | 1 | 2015 | 102 | 0.130 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2013 | 1257 | 0.130 |
Why?
|
| Antigens, Surface | 1 | 2015 | 101 | 0.130 |
Why?
|
| Vidarabine | 3 | 2010 | 141 | 0.130 |
Why?
|
| Triazoles | 1 | 2015 | 96 | 0.130 |
Why?
|
| Folic Acid | 1 | 2015 | 56 | 0.130 |
Why?
|
| Hydroxamic Acids | 1 | 2014 | 47 | 0.130 |
Why?
|
| Graft Survival | 3 | 2016 | 869 | 0.130 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2020 | 348 | 0.130 |
Why?
|
| Case-Control Studies | 3 | 2015 | 1775 | 0.130 |
Why?
|
| Immunophenotyping | 1 | 2015 | 210 | 0.130 |
Why?
|
| Microfluidics | 1 | 2015 | 51 | 0.130 |
Why?
|
| Pancreatic Neoplasms | 2 | 2017 | 632 | 0.130 |
Why?
|
| Apoptosis | 4 | 2013 | 1667 | 0.130 |
Why?
|
| Disease-Free Survival | 6 | 2016 | 1203 | 0.130 |
Why?
|
| Response Elements | 1 | 2014 | 61 | 0.130 |
Why?
|
| Carcinogenesis | 1 | 2016 | 184 | 0.120 |
Why?
|
| Structure-Activity Relationship | 1 | 2015 | 402 | 0.120 |
Why?
|
| Recurrence | 5 | 2017 | 1135 | 0.120 |
Why?
|
| Retrospective Studies | 9 | 2022 | 8037 | 0.120 |
Why?
|
| Disease Progression | 4 | 2016 | 1469 | 0.120 |
Why?
|
| DNA, Neoplasm | 2 | 2013 | 267 | 0.120 |
Why?
|
| Histocompatibility Antigens | 1 | 2013 | 35 | 0.120 |
Why?
|
| Fluorescent Antibody Technique | 3 | 2021 | 309 | 0.120 |
Why?
|
| Glucocorticoids | 1 | 2015 | 344 | 0.120 |
Why?
|
| Blood Grouping and Crossmatching | 1 | 2012 | 14 | 0.120 |
Why?
|
| Protein Structure, Tertiary | 2 | 2015 | 733 | 0.120 |
Why?
|
| Antigens, CD | 1 | 2015 | 455 | 0.120 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2014 | 148 | 0.120 |
Why?
|
| Cerebellum | 2 | 2011 | 238 | 0.120 |
Why?
|
| Chromatin | 1 | 2015 | 339 | 0.120 |
Why?
|
| Karyotyping | 2 | 2011 | 250 | 0.120 |
Why?
|
| Drug Administration Schedule | 4 | 2018 | 917 | 0.110 |
Why?
|
| Homeostasis | 2 | 2012 | 394 | 0.110 |
Why?
|
| Incidence | 5 | 2021 | 1564 | 0.110 |
Why?
|
| Point Mutation | 2 | 2012 | 247 | 0.110 |
Why?
|
| Quantitative Trait, Heritable | 1 | 2013 | 124 | 0.110 |
Why?
|
| Hemagglutinins, Viral | 1 | 1992 | 39 | 0.110 |
Why?
|
| Imatinib Mesylate | 2 | 2009 | 125 | 0.110 |
Why?
|
| Genes, BRCA1 | 2 | 2015 | 192 | 0.110 |
Why?
|
| Membrane Fusion | 1 | 1992 | 37 | 0.110 |
Why?
|
| Glioblastoma | 1 | 2014 | 245 | 0.110 |
Why?
|
| Myelopoiesis | 1 | 2011 | 10 | 0.110 |
Why?
|
| Phosphorylation | 2 | 2019 | 1104 | 0.110 |
Why?
|
| Viral Envelope Proteins | 1 | 1992 | 95 | 0.110 |
Why?
|
| Diet | 1 | 2015 | 435 | 0.110 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2012 | 125 | 0.100 |
Why?
|
| Benzamides | 2 | 2009 | 224 | 0.100 |
Why?
|
| Dinucleoside Phosphates | 1 | 2011 | 8 | 0.100 |
Why?
|
| Comorbidity | 4 | 2018 | 932 | 0.100 |
Why?
|
| Genome-Wide Association Study | 3 | 2017 | 1554 | 0.100 |
Why?
|
| Leukocyte Transfusion | 1 | 2010 | 15 | 0.100 |
Why?
|
| Graft vs Tumor Effect | 1 | 2010 | 25 | 0.100 |
Why?
|
| Biotin | 1 | 2010 | 43 | 0.100 |
Why?
|
| Carbazoles | 1 | 2011 | 51 | 0.100 |
Why?
|
| Hepatic Veno-Occlusive Disease | 1 | 2010 | 19 | 0.100 |
Why?
|
| Busulfan | 1 | 2010 | 38 | 0.100 |
Why?
|
| Codon, Nonsense | 1 | 2010 | 38 | 0.100 |
Why?
|
| Catalytic Domain | 1 | 2011 | 157 | 0.100 |
Why?
|
| DNA Mismatch Repair | 1 | 2010 | 52 | 0.100 |
Why?
|
| Piperazines | 2 | 2009 | 268 | 0.100 |
Why?
|
| Staining and Labeling | 1 | 2010 | 163 | 0.100 |
Why?
|
| Salvage Therapy | 2 | 2011 | 228 | 0.100 |
Why?
|
| Family Health | 1 | 2010 | 162 | 0.100 |
Why?
|
| Substrate Specificity | 1 | 2011 | 344 | 0.100 |
Why?
|
| Microfilament Proteins | 3 | 2001 | 204 | 0.100 |
Why?
|
| Kidney | 1 | 1996 | 1197 | 0.090 |
Why?
|
| Graft Rejection | 1 | 2016 | 1052 | 0.090 |
Why?
|
| Precancerous Conditions | 1 | 2011 | 194 | 0.090 |
Why?
|
| Oligodeoxyribonucleotides | 2 | 2008 | 126 | 0.090 |
Why?
|
| Neutropenia | 1 | 2010 | 213 | 0.090 |
Why?
|
| Transplantation Chimera | 1 | 2009 | 78 | 0.090 |
Why?
|
| Tissue Distribution | 3 | 2000 | 286 | 0.090 |
Why?
|
| Cohort Studies | 2 | 2014 | 2695 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 22 | 1 | 2009 | 43 | 0.090 |
Why?
|
| Transfer RNA Aminoacylation | 1 | 2009 | 18 | 0.090 |
Why?
|
| Crystallography, X-Ray | 1 | 2011 | 480 | 0.090 |
Why?
|
| Proteasome Inhibitors | 1 | 2009 | 50 | 0.090 |
Why?
|
| Boronic Acids | 1 | 2009 | 54 | 0.090 |
Why?
|
| Polymorphism, Genetic | 1 | 2013 | 817 | 0.090 |
Why?
|
| Sequence Homology, Amino Acid | 3 | 2015 | 415 | 0.090 |
Why?
|
| Protease Inhibitors | 1 | 2009 | 70 | 0.090 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2012 | 266 | 0.090 |
Why?
|
| Outpatients | 1 | 2009 | 87 | 0.090 |
Why?
|
| Pyrazines | 1 | 2009 | 84 | 0.090 |
Why?
|
| Neoplasm Staging | 4 | 2018 | 1930 | 0.090 |
Why?
|
| Heart | 1 | 2012 | 519 | 0.090 |
Why?
|
| Leukemia, Mast-Cell | 1 | 2008 | 5 | 0.090 |
Why?
|
| Kruppel-Like Factor 6 | 1 | 2008 | 4 | 0.090 |
Why?
|
| Proportional Hazards Models | 4 | 2016 | 851 | 0.090 |
Why?
|
| Infant | 3 | 2021 | 2986 | 0.090 |
Why?
|
| RNA, Neoplasm | 1 | 2008 | 85 | 0.090 |
Why?
|
| Thionucleotides | 1 | 2008 | 56 | 0.080 |
Why?
|
| Child, Preschool | 3 | 2021 | 3566 | 0.080 |
Why?
|
| Blood Component Removal | 1 | 2008 | 24 | 0.080 |
Why?
|
| Quinoxalines | 1 | 2008 | 50 | 0.080 |
Why?
|
| Hippocampus | 1 | 2011 | 435 | 0.080 |
Why?
|
| Acute Kidney Injury | 1 | 2011 | 276 | 0.080 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2008 | 92 | 0.080 |
Why?
|
| Sequence Deletion | 1 | 2008 | 204 | 0.080 |
Why?
|
| C-Reactive Protein | 1 | 2008 | 189 | 0.080 |
Why?
|
| RNA, Transfer | 1 | 2009 | 145 | 0.080 |
Why?
|
| Genome | 1 | 2010 | 360 | 0.080 |
Why?
|
| Maximum Tolerated Dose | 3 | 2014 | 270 | 0.080 |
Why?
|
| Mycoses | 1 | 2007 | 44 | 0.080 |
Why?
|
| Adenosine Triphosphate | 1 | 2008 | 310 | 0.080 |
Why?
|
| Neoplasm, Residual | 2 | 2022 | 156 | 0.080 |
Why?
|
| Amino Acid Sequence | 4 | 2015 | 2057 | 0.080 |
Why?
|
| Tumor Cells, Cultured | 3 | 2020 | 1030 | 0.080 |
Why?
|
| Transplantation, Haploidentical | 2 | 2017 | 27 | 0.080 |
Why?
|
| Karnofsky Performance Status | 1 | 2006 | 40 | 0.080 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2021 | 267 | 0.070 |
Why?
|
| Leukocytes | 1 | 2007 | 200 | 0.070 |
Why?
|
| Radiotherapy | 1 | 2008 | 325 | 0.070 |
Why?
|
| Ganciclovir | 1 | 2006 | 49 | 0.070 |
Why?
|
| Flow Cytometry | 2 | 2021 | 668 | 0.070 |
Why?
|
| Valine | 1 | 2006 | 69 | 0.070 |
Why?
|
| Leukocyte Count | 2 | 2016 | 215 | 0.070 |
Why?
|
| Lung | 1 | 2012 | 1122 | 0.070 |
Why?
|
| Acyclovir | 1 | 2006 | 105 | 0.070 |
Why?
|
| Introns | 2 | 2013 | 283 | 0.070 |
Why?
|
| Caenorhabditis elegans | 1 | 2007 | 216 | 0.070 |
Why?
|
| Prevalence | 2 | 2020 | 1209 | 0.070 |
Why?
|
| Registries | 2 | 2021 | 684 | 0.070 |
Why?
|
| Cloning, Molecular | 2 | 2012 | 644 | 0.070 |
Why?
|
| Cytomegalovirus Infections | 1 | 2006 | 144 | 0.070 |
Why?
|
| Bone Marrow Transplantation | 1 | 2006 | 286 | 0.070 |
Why?
|
| Practice Guidelines as Topic | 1 | 2012 | 1033 | 0.070 |
Why?
|
| Infant, Newborn | 2 | 2021 | 2318 | 0.070 |
Why?
|
| Ovarian Neoplasms | 1 | 2011 | 711 | 0.060 |
Why?
|
| Blotting, Western | 2 | 2021 | 773 | 0.060 |
Why?
|
| Lymphocyte Activation | 2 | 2019 | 715 | 0.060 |
Why?
|
| DNA Primers | 3 | 2002 | 537 | 0.060 |
Why?
|
| Transcriptome | 2 | 2020 | 545 | 0.060 |
Why?
|
| Conserved Sequence | 2 | 2015 | 208 | 0.060 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2023 | 586 | 0.060 |
Why?
|
| Immunotherapy | 1 | 2009 | 593 | 0.060 |
Why?
|
| Microarray Analysis | 2 | 2015 | 96 | 0.060 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 2 | 2000 | 29 | 0.060 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 3 | 2013 | 682 | 0.060 |
Why?
|
| Methylation | 2 | 2015 | 244 | 0.060 |
Why?
|
| Polycomb Repressive Complex 2 | 1 | 2022 | 29 | 0.060 |
Why?
|
| Doxorubicin | 2 | 2013 | 284 | 0.060 |
Why?
|
| Enzyme Activation | 2 | 2021 | 689 | 0.060 |
Why?
|
| World Health Organization | 1 | 2022 | 101 | 0.060 |
Why?
|
| Porosity | 2 | 2015 | 59 | 0.050 |
Why?
|
| Cytogenetics | 1 | 2021 | 27 | 0.050 |
Why?
|
| Benzothiazoles | 1 | 2021 | 17 | 0.050 |
Why?
|
| Gene Regulatory Networks | 2 | 2017 | 281 | 0.050 |
Why?
|
| Antiviral Agents | 1 | 2006 | 494 | 0.050 |
Why?
|
| Polymerase Chain Reaction | 3 | 2013 | 921 | 0.050 |
Why?
|
| Prospective Studies | 4 | 2014 | 4076 | 0.050 |
Why?
|
| Syndrome | 1 | 2022 | 432 | 0.050 |
Why?
|
| HeLa Cells | 2 | 2015 | 494 | 0.050 |
Why?
|
| Reproducibility of Results | 2 | 2019 | 2647 | 0.050 |
Why?
|
| Heterozygote | 1 | 2022 | 362 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2022 | 187 | 0.050 |
Why?
|
| Naphthyridines | 1 | 2021 | 51 | 0.050 |
Why?
|
| Physical Chromosome Mapping | 1 | 2001 | 27 | 0.050 |
Why?
|
| California | 1 | 2021 | 135 | 0.050 |
Why?
|
| Drug Synergism | 1 | 2021 | 303 | 0.050 |
Why?
|
| Muscle Hypotonia | 1 | 2021 | 42 | 0.050 |
Why?
|
| Microcephaly | 1 | 2021 | 74 | 0.050 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2011 | 863 | 0.050 |
Why?
|
| Follow-Up Studies | 2 | 2021 | 3600 | 0.050 |
Why?
|
| Illinois | 2 | 2012 | 459 | 0.050 |
Why?
|
| Animals, Newborn | 2 | 2012 | 507 | 0.050 |
Why?
|
| Chromosome Breakage | 1 | 2020 | 16 | 0.050 |
Why?
|
| Cell Lineage | 2 | 2011 | 263 | 0.050 |
Why?
|
| Methyltransferases | 1 | 2021 | 175 | 0.050 |
Why?
|
| Feasibility Studies | 1 | 2022 | 741 | 0.050 |
Why?
|
| Connectin | 1 | 1999 | 6 | 0.050 |
Why?
|
| Carrier Proteins | 2 | 2001 | 662 | 0.050 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2020 | 87 | 0.050 |
Why?
|
| Recombinant Proteins | 2 | 2015 | 1008 | 0.050 |
Why?
|
| Quality of Life | 1 | 2007 | 1491 | 0.050 |
Why?
|
| Developmental Disabilities | 1 | 2021 | 192 | 0.050 |
Why?
|
| Molecular Weight | 1 | 1999 | 331 | 0.050 |
Why?
|
| Molecular Dynamics Simulation | 1 | 2021 | 239 | 0.050 |
Why?
|
| Mammary Tumor Virus, Mouse | 2 | 1996 | 63 | 0.040 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 2 | 1996 | 134 | 0.040 |
Why?
|
| Consolidation Chemotherapy | 1 | 2018 | 21 | 0.040 |
Why?
|
| DNA, Complementary | 1 | 1999 | 391 | 0.040 |
Why?
|
| Expert Testimony | 1 | 2018 | 47 | 0.040 |
Why?
|
| Disease Models, Animal | 3 | 2015 | 2184 | 0.040 |
Why?
|
| Aneuploidy | 2 | 1996 | 55 | 0.040 |
Why?
|
| Motor Activity | 1 | 2021 | 325 | 0.040 |
Why?
|
| Lactobacillus | 1 | 2018 | 21 | 0.040 |
Why?
|
| Paraproteins | 1 | 2018 | 3 | 0.040 |
Why?
|
| Maintenance Chemotherapy | 1 | 2018 | 76 | 0.040 |
Why?
|
| Wnt Proteins | 5 | 1997 | 123 | 0.040 |
Why?
|
| Cyclin D2 | 1 | 2018 | 19 | 0.040 |
Why?
|
| Hydrogen Peroxide | 1 | 2019 | 154 | 0.040 |
Why?
|
| Penetrance | 1 | 2018 | 43 | 0.040 |
Why?
|
| Cluster Analysis | 2 | 2011 | 362 | 0.040 |
Why?
|
| Li-Fraumeni Syndrome | 1 | 2018 | 5 | 0.040 |
Why?
|
| Cytoskeletal Proteins | 1 | 1999 | 221 | 0.040 |
Why?
|
| Preoperative Period | 1 | 2018 | 91 | 0.040 |
Why?
|
| Toll-Like Receptor 2 | 1 | 2018 | 32 | 0.040 |
Why?
|
| Permeability | 1 | 2018 | 132 | 0.040 |
Why?
|
| Germ-Free Life | 1 | 2018 | 69 | 0.040 |
Why?
|
| United States | 2 | 2021 | 6414 | 0.040 |
Why?
|
| Oxidation-Reduction | 1 | 2019 | 372 | 0.040 |
Why?
|
| Immunosuppressive Agents | 2 | 2015 | 967 | 0.040 |
Why?
|
| Infusions, Intravenous | 2 | 2009 | 431 | 0.040 |
Why?
|
| Superoxide Dismutase | 1 | 2019 | 177 | 0.040 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2018 | 80 | 0.040 |
Why?
|
| Patient-Specific Modeling | 1 | 2017 | 19 | 0.040 |
Why?
|
| Plasma Cells | 1 | 2018 | 80 | 0.040 |
Why?
|
| Radiation Exposure | 1 | 2017 | 22 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 7 | 1 | 2017 | 79 | 0.040 |
Why?
|
| Neoplasm Grading | 1 | 2018 | 336 | 0.040 |
Why?
|
| Cause of Death | 1 | 2018 | 273 | 0.040 |
Why?
|
| Postoperative Complications | 1 | 2007 | 2194 | 0.040 |
Why?
|
| Neoplasm Transplantation | 1 | 2017 | 386 | 0.040 |
Why?
|
| Predictive Value of Tests | 2 | 2014 | 1635 | 0.040 |
Why?
|
| Transfection | 2 | 2010 | 882 | 0.040 |
Why?
|
| Databases, Nucleic Acid | 1 | 2016 | 41 | 0.040 |
Why?
|
| Bacterial Infections | 1 | 2018 | 179 | 0.040 |
Why?
|
| Blood Urea Nitrogen | 1 | 1996 | 34 | 0.040 |
Why?
|
| Gene Knock-In Techniques | 1 | 2016 | 26 | 0.040 |
Why?
|
| Texas | 1 | 2016 | 99 | 0.040 |
Why?
|
| Leukemic Infiltration | 1 | 2015 | 14 | 0.040 |
Why?
|
| Chimerism | 1 | 2016 | 37 | 0.040 |
Why?
|
| Multiplex Polymerase Chain Reaction | 1 | 2015 | 33 | 0.040 |
Why?
|
| Histocompatibility | 1 | 2016 | 70 | 0.040 |
Why?
|
| Bone Marrow Diseases | 1 | 2015 | 40 | 0.040 |
Why?
|
| Oxidative Stress | 1 | 2019 | 442 | 0.040 |
Why?
|
| Workflow | 1 | 2016 | 74 | 0.040 |
Why?
|
| Mesoderm | 1 | 1996 | 98 | 0.040 |
Why?
|
| Antigens, Differentiation | 1 | 1996 | 139 | 0.040 |
Why?
|
| In Situ Hybridization | 1 | 1996 | 303 | 0.030 |
Why?
|
| Gene Deletion | 2 | 2011 | 327 | 0.030 |
Why?
|
| Drosophila Proteins | 1 | 2000 | 479 | 0.030 |
Why?
|
| Genomic Instability | 1 | 2015 | 75 | 0.030 |
Why?
|
| Neoplasm Metastasis | 1 | 2019 | 1048 | 0.030 |
Why?
|
| Europe | 1 | 2016 | 304 | 0.030 |
Why?
|
| Organ Size | 1 | 1996 | 355 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p15 | 1 | 2014 | 24 | 0.030 |
Why?
|
| MCF-7 Cells | 1 | 2015 | 104 | 0.030 |
Why?
|
| Mortality | 1 | 2016 | 148 | 0.030 |
Why?
|
| Proto-Oncogenes | 2 | 2010 | 61 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2014 | 74 | 0.030 |
Why?
|
| Cell Division | 2 | 2011 | 692 | 0.030 |
Why?
|
| Genes, BRCA2 | 1 | 2015 | 159 | 0.030 |
Why?
|
| Transplant Recipients | 1 | 2015 | 112 | 0.030 |
Why?
|
| Neutrophils | 1 | 2016 | 301 | 0.030 |
Why?
|
| Genes, Reporter | 1 | 2015 | 263 | 0.030 |
Why?
|
| Cocarcinogenesis | 1 | 1994 | 12 | 0.030 |
Why?
|
| Genetics, Medical | 1 | 2014 | 49 | 0.030 |
Why?
|
| Recombinant Fusion Proteins | 1 | 1996 | 550 | 0.030 |
Why?
|
| Cadherins | 1 | 2015 | 148 | 0.030 |
Why?
|
| Survivors | 1 | 2015 | 217 | 0.030 |
Why?
|
| Smad1 Protein | 1 | 2013 | 3 | 0.030 |
Why?
|
| Chromosome Mapping | 2 | 2011 | 1066 | 0.030 |
Why?
|
| Glycosyltransferases | 1 | 2013 | 19 | 0.030 |
Why?
|
| Single-Cell Analysis | 1 | 2015 | 114 | 0.030 |
Why?
|
| Caspase 8 | 1 | 2013 | 34 | 0.030 |
Why?
|
| Mice, Mutant Strains | 1 | 2013 | 228 | 0.030 |
Why?
|
| Injections, Subcutaneous | 1 | 2013 | 116 | 0.030 |
Why?
|
| Immunoglobulin Isotypes | 1 | 2013 | 32 | 0.030 |
Why?
|
| Pneumococcal Vaccines | 1 | 2013 | 27 | 0.030 |
Why?
|
| Cyclin D1 | 1 | 2013 | 82 | 0.030 |
Why?
|
| beta Catenin | 1 | 2015 | 243 | 0.030 |
Why?
|
| Referral and Consultation | 1 | 2016 | 321 | 0.030 |
Why?
|
| Computational Biology | 1 | 2016 | 525 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 1 | 2015 | 521 | 0.030 |
Why?
|
| Lymphocyte Subsets | 1 | 2013 | 63 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 1 | 2015 | 1034 | 0.030 |
Why?
|
| Oncogene Proteins | 1 | 2013 | 58 | 0.030 |
Why?
|
| Caspase 3 | 1 | 2013 | 158 | 0.030 |
Why?
|
| Lymphocyte Count | 1 | 2013 | 92 | 0.030 |
Why?
|
| Intestinal Mucosa | 1 | 2018 | 789 | 0.030 |
Why?
|
| Epistasis, Genetic | 1 | 2013 | 85 | 0.030 |
Why?
|
| Inflammation | 1 | 2018 | 874 | 0.030 |
Why?
|
| Wnt1 Protein | 3 | 1997 | 24 | 0.030 |
Why?
|
| Bromelains | 1 | 1992 | 1 | 0.030 |
Why?
|
| Virus Diseases | 1 | 2013 | 97 | 0.030 |
Why?
|
| Databases, Genetic | 1 | 2013 | 255 | 0.030 |
Why?
|
| Binding Sites, Antibody | 1 | 1992 | 49 | 0.030 |
Why?
|
| Trypsin | 1 | 1992 | 95 | 0.030 |
Why?
|
| Antigens, Nuclear | 1 | 2012 | 25 | 0.030 |
Why?
|
| Hemagglutinin Glycoproteins, Influenza Virus | 1 | 1992 | 71 | 0.030 |
Why?
|
| Sulfites | 1 | 2012 | 26 | 0.030 |
Why?
|
| Methyl-CpG-Binding Protein 2 | 1 | 2011 | 16 | 0.030 |
Why?
|
| Phosphopyruvate Hydratase | 1 | 2011 | 39 | 0.030 |
Why?
|
| Erythrocytes | 1 | 2013 | 252 | 0.030 |
Why?
|
| Validation Studies as Topic | 1 | 2011 | 16 | 0.030 |
Why?
|
| Rett Syndrome | 1 | 2011 | 19 | 0.030 |
Why?
|
| Quinazolines | 1 | 2013 | 217 | 0.030 |
Why?
|
| Colony-Forming Units Assay | 1 | 2011 | 40 | 0.030 |
Why?
|
| Adult Stem Cells | 1 | 2011 | 30 | 0.030 |
Why?
|
| Tissue Array Analysis | 1 | 2012 | 123 | 0.030 |
Why?
|
| Granulocytes | 1 | 2011 | 36 | 0.030 |
Why?
|
| Immunoprecipitation | 1 | 2011 | 132 | 0.030 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 1992 | 272 | 0.030 |
Why?
|
| Lentivirus | 1 | 2011 | 35 | 0.030 |
Why?
|
| DNA Damage | 1 | 2013 | 356 | 0.030 |
Why?
|
| Sheep | 1 | 2011 | 227 | 0.030 |
Why?
|
| Core Binding Factors | 1 | 2011 | 12 | 0.030 |
Why?
|
| Gene Knockout Techniques | 1 | 2011 | 76 | 0.030 |
Why?
|
| CCCTC-Binding Factor | 1 | 2011 | 12 | 0.030 |
Why?
|
| Furans | 1 | 2011 | 16 | 0.030 |
Why?
|
| X Chromosome | 1 | 2011 | 151 | 0.030 |
Why?
|
| MDS1 and EVI1 Complex Locus Protein | 1 | 2010 | 6 | 0.030 |
Why?
|
| Bacteriophage T4 | 1 | 2010 | 8 | 0.030 |
Why?
|
| Hydroxylation | 1 | 2010 | 16 | 0.030 |
Why?
|
| Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2011 | 26 | 0.030 |
Why?
|
| GATA1 Transcription Factor | 1 | 2010 | 18 | 0.030 |
Why?
|
| Cricetinae | 1 | 1992 | 558 | 0.030 |
Why?
|
| Kidney Failure, Chronic | 1 | 1996 | 489 | 0.030 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 1 | 2011 | 73 | 0.030 |
Why?
|
| Organ Specificity | 1 | 2011 | 253 | 0.030 |
Why?
|
| Glucosyltransferases | 1 | 2010 | 25 | 0.030 |
Why?
|
| Genes, ras | 1 | 2011 | 97 | 0.030 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2010 | 67 | 0.030 |
Why?
|
| Diarrhea | 1 | 2012 | 181 | 0.030 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 1992 | 489 | 0.030 |
Why?
|
| Protein Binding | 1 | 2014 | 1443 | 0.030 |
Why?
|
| Metabolic Clearance Rate | 1 | 2010 | 121 | 0.020 |
Why?
|
| Mutant Proteins | 1 | 2011 | 94 | 0.020 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2013 | 363 | 0.020 |
Why?
|
| Valproic Acid | 1 | 2010 | 21 | 0.020 |
Why?
|
| Thrombospondin 1 | 1 | 2010 | 21 | 0.020 |
Why?
|
| Stem Cells | 1 | 2013 | 342 | 0.020 |
Why?
|
| Acetylation | 1 | 2010 | 123 | 0.020 |
Why?
|
| Models, Animal | 1 | 2011 | 257 | 0.020 |
Why?
|
| Drug Combinations | 1 | 2010 | 217 | 0.020 |
Why?
|
| Cell Shape | 1 | 2010 | 50 | 0.020 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2010 | 131 | 0.020 |
Why?
|
| Monocytes | 1 | 2011 | 212 | 0.020 |
Why?
|
| Glomerular Filtration Rate | 1 | 2011 | 379 | 0.020 |
Why?
|
| Genetic Vectors | 1 | 2011 | 434 | 0.020 |
Why?
|
| CD3 Complex | 1 | 2009 | 135 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2011 | 911 | 0.020 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2011 | 258 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2011 | 461 | 0.020 |
Why?
|
| Bortezomib | 1 | 2009 | 74 | 0.020 |
Why?
|
| Protein Conformation | 1 | 1992 | 879 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2011 | 815 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2010 | 502 | 0.020 |
Why?
|
| Myeloablative Agonists | 1 | 2008 | 34 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2010 | 604 | 0.020 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2001 | 290 | 0.020 |
Why?
|
| Half-Life | 1 | 2008 | 95 | 0.020 |
Why?
|
| Filgrastim | 1 | 2008 | 56 | 0.020 |
Why?
|
| Stereoisomerism | 1 | 2008 | 102 | 0.020 |
Why?
|
| Tacrolimus | 1 | 2009 | 369 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2019 | 3178 | 0.020 |
Why?
|
| Cytogenetic Analysis | 1 | 2008 | 71 | 0.020 |
Why?
|
| Molecular Structure | 1 | 2008 | 284 | 0.020 |
Why?
|
| Protein Transport | 1 | 2009 | 407 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2013 | 1746 | 0.020 |
Why?
|
| Protein Biosynthesis | 1 | 2009 | 373 | 0.020 |
Why?
|
| Receptors, Cell Surface | 1 | 2008 | 280 | 0.020 |
Why?
|
| Antifungal Agents | 1 | 2007 | 110 | 0.020 |
Why?
|
| Transplantation, Autologous | 1 | 2008 | 323 | 0.020 |
Why?
|
| Liver Diseases | 1 | 2008 | 228 | 0.020 |
Why?
|
| Hyperplasia | 2 | 1997 | 146 | 0.020 |
Why?
|
| Crosses, Genetic | 2 | 1997 | 169 | 0.020 |
Why?
|
| Mammary Glands, Animal | 2 | 1997 | 78 | 0.020 |
Why?
|
| Length of Stay | 1 | 2008 | 683 | 0.020 |
Why?
|
| Rats | 1 | 2012 | 3935 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2008 | 1967 | 0.020 |
Why?
|
| Chromosomes, Artificial, Human | 1 | 2001 | 2 | 0.010 |
Why?
|
| Apc8 Subunit, Anaphase-Promoting Complex-Cyclosome | 1 | 2001 | 2 | 0.010 |
Why?
|
| Nuclear Localization Signals | 1 | 2000 | 10 | 0.010 |
Why?
|
| Gene Library | 1 | 2001 | 125 | 0.010 |
Why?
|
| Time Factors | 1 | 2009 | 5174 | 0.010 |
Why?
|
| Consensus Sequence | 1 | 2000 | 62 | 0.010 |
Why?
|
| Tandem Repeat Sequences | 1 | 2000 | 26 | 0.010 |
Why?
|
| Amino Acid Motifs | 1 | 2000 | 113 | 0.010 |
Why?
|
| Open Reading Frames | 1 | 2000 | 117 | 0.010 |
Why?
|
| Insect Proteins | 1 | 2000 | 88 | 0.010 |
Why?
|
| Sequence Alignment | 1 | 2000 | 351 | 0.010 |
Why?
|
| Mitosis | 1 | 1997 | 149 | 0.010 |
Why?
|
| RNA Polymerase III | 1 | 1996 | 7 | 0.010 |
Why?
|
| Mitogens | 1 | 1996 | 63 | 0.010 |
Why?
|
| Drosophila | 1 | 2000 | 490 | 0.010 |
Why?
|
| Gene Targeting | 1 | 1996 | 71 | 0.010 |
Why?
|
| Fibrosis | 1 | 1995 | 194 | 0.010 |
Why?
|
| Neoplasms, Experimental | 1 | 1996 | 270 | 0.010 |
Why?
|
| Fibroblast Growth Factors | 1 | 1994 | 78 | 0.010 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 1994 | 153 | 0.010 |
Why?
|